arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Gossamer Bio, Inc.

GOSS
$9.44 ▼ -0.51 (-5.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
10 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
46
Health
Weak
Moderately Bearish
auto_awesome

Analytical Summary

Gossamer Bio, Inc. faces fundamental challenges. On the positive side, Return on Common Equity (%) remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.2B
Dividend Yield —
Revenue Growth -57.7%
Op. Margin -352.2% ↘
ROIC 139.0% ↗
FCF / Share $-0.75 ↘
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

10-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$48.47M
↓ -57.7% —
Net Income Profit after all expenses
$-170.37M
↓ -201.4% —
Operating Margin Operating profit as % of sales
-352.2%
↓ -574.3% 0th
FCF / Share Free cash flow per share
$-0.75
↓ -4791.2% —
Long-Term Debt Long-term obligations
$0.00
↓ -100.0% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns
100
Financial Health ↓
26
Cash Quality ↑
66

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 10 years · 36 quarters